You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Inoa JO, Escudero LS, Manzano A, et al
2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era
International Journal of Gynecologic Cancer 2022;32:A306.